This study is being conducted to assess the performance of the BD Veritor™ Plus System for Rapid Detection of SARS-CoV-2, used in serial testing, in identification of infectious, asymptomatic individuals. This information may be used to inform development of an effective testing strategy by policy makers.
This multi-center, prospective, observational, diagnostic evaluation study is designed to assess the performance of the BD Veritor System in the detection of SARS-CoV-2 in asymptomatic individuals compared to viral culture and a commercially available RT-PCR assay over multiple testing time points. The study will enroll a minimum of 150 asymptomatic, adult participants who test positive for SARS-CoV-2 during community/traveler screening procedures.
Study Type
OBSERVATIONAL
Nasal Sawb for the conduct of the Veritor Antigen Test
Nasopharyngeal Swab for the conduct of a rt-PCR
Nasopharyngeal Swab for the conduct of viral culture
Changi General Hospital
Singapore, Singapore
Assess the performance of the BD Veritor System for Rapid Detection of SARS-CoV-2 compared viral culture, over multiple collection time points
* Assay results: Positive percent agreement (PPA) * Assay results: Negative percent agreement (NPA)
Time frame: 6 days
Assess the performance of the BD Veritor System for Rapid Detection of SARS-CoV-2 compared to a commercially available RT-PCR asay, over multiple collection time points
* Assay results: Positive percent agreement (PPA) * Assay results: Negative percent agreement (NPA)
Time frame: 6 days
Assess the performance a commercially available RT-PCR assay compared to viral culture, over multiple test time points
* Assay results: Positive percent agreement (PPA) * Assay results: Negative percent agreement (NPA)
Time frame: 6 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.